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Abstract
Background: Adult minimal changes disease (MCD) is usually treated by high corticosteroids
dose in order to achieve remission of nephrotic syndrome. In this study, the administration of high
steroid dose (prednisolone 1 mg/kg BW/day) is compared with the combination of lower
prednisolone dose (0.3 mg/kg BW/day) and cyclosporine A (CsA) (2–3 mg/kg BW/day) in a small
number of patients.
Findings: Eighteen patients were allocated to either prednisolone monotherapy or prednisolone
and CsA combination, according to the risk of developing steroid side-effects. Complete remission
of the nephrotic syndrome was observed in all patients treated by steroids or combination of
steroids and CsA. Complete remission occurred in 67%, 89% and 100% of patients after 4, 8 and
12 weeks of treatment. Relapses occurred in 50% of patients from both groups, treated with the
combination of low prednisolone dose and CsA and followed by sustained remission.
Corticosteroidal side effects were observed only in high prednisolone dose (accumulated dose:
92.7 ± 22 mg/kg/BW vs. 58.5 ± 21 mg/kg/BW, p = 0.004).
Conclusion: Treatment of adult MCD with low prednisolone dose and CsA seems to be equally
effective with high prednisolone dose to induce remission of nephrotic syndrome. It is also effective
as maintenance therapy for prevention of relapses and less frequently followed by corticosteroidal
side effects.
Background
Minimal changes disease (MCD) represens the most com-
mon cause of nephrotic syndrome in children accounting
for more than 70% of cases, but it 's also the cause of adult
nephrotic syndrome in 10 to 25% of cases [1,2]. The
pathogenesis remains unknown. A shift of the T-cell rep-
ertoire, towards a Th-2 phenotype leading to release of
putative permeability factors, is postulated [3]. Corticos-
teroids restore the glomerular expression of dystroglycans,
adhesion molecules of foot processes, that are reduced in
MCD patients with nephrotic syndrome [4,5].
Complete remission of proteinuria occurs in 90% of cor-
ticosteroid-treated children, early after initiation of treat-
ment [6]. However, this period is longer in adults,
whereas a large percentage of them shows relapses or
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becomes steroid-dependent [7]. Longer duration of treat-
ment with high steroid doses increases the risk of serious
side effects [2,8,9]. Cyclophosphamide and chlorambucil
have been used in patients with frequent relapses, as
maintenance therapy to prevent relapses and resulted in
sustained remission [7], while the use of azathioprine and
mycophenolate mofetil is rather limited [10].
CsA is used in patients with MCD, who continue to
relapse after a course of alkylating agents, in cases with
primary steroid resistance and recently as an initial treat-
ment in children with steroid-sensitive nephrotic syn-
drome, in order to reduce the number of relapses [11].
However, CsA has not been used as an initial treatment in
adult MCD. In this study the effect of prednisolone mon-
otherapy (1 mg/kg BW/day) is compared to that of com-
bination of lower prednisolone dose (0.3 mg/kg BW/day)
with CsA, given in a small number of patients with MCD
and a risk to high steroid dosage (obesity, borderline dia-
betes mellitus, osteoporosis and history of peptic ulcer).
Methods
Patients
Eighteen adult patients (8 males and 10 females) with
nephrotic syndrome (urinary protein: 12 ± 6 g/24 h), due
to biopsy-proven minimal changes disease, and well pre-
served renal function (baseline serum creatinine: 0.97 ±
0.3 mg/dl), referred to our department between 1998 and
2005, were included in the study. The inclusion criteria
were age between 18 and 65 years old, urinary protein
>3.5 g/24 h and creatinine clearance >60 ml/min. The
clinical and biochemical features of patients at presenta-
tion are shown in table 1.
All patients were treated by either prednisolone alone or
combination of lower prednisolone dose with CsA
(Neoral). The latter was given to patients with obesity
(body mass index >30 kg/m2), fasting blood glucose
between 100 and 120 mg/dl, osteoporosis and peptic
ulcer, diagnosed by endoscopy, in order to avoid high
prednisolone doses. Ten patients were treated with pred-
nisolone monotherapy (initial dose 1 mg/kgBW/day) and
eight patients with lower prednisolone (0.3 mg/kgBW/
day) and cyclosporine (2–3 mg/kg BW/day). The dose of
CsA was adjusted to maintain trough blood levels of 100
ng/ml for 12 months, mean CsA dose: 2.07 ± 0.5 mg/
kgBW/day, gradually reduced to 0.5 mg/kg BW/day per
month. Prednisolone was also gradually reduced and dis-
continued after 6 months, at least. The two different treat-
ment protocols are presented in table 2. The mean
duration of treatment with prednisolone was 13 ± 5
months and that of cyclosporin 23 ± 10 months. The total
accumulated dose of corticosteroids were significantly
higher in patients treated by high steroid dose compared
to the combination treated group (92.7 ± 22 mg/kg vs.
58.5 ± 21 mg/kg, p = 0.004) (table 2).
Patients from both groups, who showed relapses of the
nephrotic syndrome, were treated with low prednisolone
(0.3 mg/kg BW/day) and CsA (2–3 mg/kg BW/day),
regardless of initial treatment, in order to avoid the
administration of higher prednisolone doses.
Conventional histopathology and grading of 
histopathological involvement
The diagnosis was made by renal biopsy on light-micros-
copy (LM) and immunoflurescence (IF). Minimal changes
was diagnosed by the presence of normal glomeruli or
mild mesangial matrix increase and focal mesangial
hypercellularity in the LM [8]. Lack of immune deposits
and complement components, as well as presence of scat-
tered mesangial IgM deposits, were the main features in
IF.
The degree of glomerular sclerosis, interstitial edema and
fibrosis, as well as tubular atrophy and arteriolar hyalino-
sis, were evaluated from Masson's trichrome stained sec-
tions of each biopsy. The severity of glomerular sclerosis






Gender (M/F) 5/5 3/5 NS
Age (years) 39 ± 14 44 ± 18 NS
Blood pressure (mmHg) 135/83 137/86 NS
Serum creatinin (mg/dl) 0.95 ± 0.4 1.0 ± 0.2 NS
Albumin (g/L) 23 ± 3 22 ± 6 NS
Urinary protein (g/24 h) 10 ± 5 9 ± 9 NS
Glomerulosclerosis (%) 10 ± 7 10.5 ± 4 NS
Interstitial fibrosis (absent/present) 8/2 7/1 NS
Interstitial edema (absent/present) 0/10 0/8 NS
Tubular atrophy (absent/present) 8/2 5/3 NS
Vascular hyalinosis (absent/present) 6/4 5/3 NSBMC Research Notes 2009, 2:144 http://www.biomedcentral.com/1756-0500/2/144
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was expressed as the percentage of totally sclerosed
glomeruli, whereas other parameters were evaluated by a
semi-quantitative method and expressed as present or
absent [12].
Follow-up – Definition
During treatment and follow-up period, all patients were
examined every month. Body weight, blood preassure,
urinalysis, full-blood count, biochemical profile and 24 h
urinary protein were recorded. Blood pressure control,
(135/85 mmHg) was achieved by ACEi, calcium-channel
blockers, beta-blockers and diuretics in both groups of
patients.
Remission of nephrotic syndrome was defined as com-
plete or partial if proteinuria was <0.3 g/24 h and between
0.3 and 3 g/24 h respectively. Relapse was considered
when edema and proteinuria >3.5 g/24 h re-appeared, in
patients with remission. The follow-up period was 6 ± 3
years. The development of chronic renal failure was esti-
mated using the end-points of 50% and 100% increase
(doubling) of base-line serum creatinine.
Statistical analysis
Variables are presented as mean ± SD. Unpaired t-test was
used to compare baseline clinical and biochemical data,
between the two groups of patients. Chi-square test for
independence, was used to compare histopathological
data and remission rate of proteinuria, in the two groups
of patients. A p-value of less than or equal to 0.05 was
considered to be statistically significant.
Results
Remission of nephrotic syndrome
Complete remission of nephrotic syndrome was observed
in all patients treated by either high steroid dose or com-
bination of low steroid dose and CsA. The number of
patients from both groups with complete remission after
4, 8 and 12 weeks of treatment was 12 (67%), 16 (89%)
and 18 (100%) respectively. At 4 weeks, 7 patients from
the steroid treated group and 5 from the combination
treated group, showed complete remission (p = NS). At 8
weeks all steroid treated and 6 from the steroid and CsA
treated group presented complete remission (p = NS),
whereas at 12 weeks all patients from both groups were in
complete remission (Fig. 1, 2, 3 and 4).
Relapses of the nephrotic syndrome
Relapses occurred in 9 patients (50%), 4 initially treated
with steroids and 5 with combination of lower steroid
dose and CsA (p = NS). Seven patients showed the first
episode of relapse, during tapering of steroid or CsA dose,
whereas 2 showed relapse one and six months after dis-
continuation of treatment. All relapsers were treated by
low prednisolone dose and CsA and showed complete
remission. Two of 9 patients (22%) showed more than 2
episodes of relapse and treated for a longer period of time
(40 and 36 months respectively), using a long-term low
maintenance dose of CsA (1 mg mg/kg BW/day). Since
renal function is not a reliable indicator of CsA nephro-
toxicity and histological examination is necessary [13],
these two patients underwent a repeat renal biopsy, in
order to identify potential CsA nephrotoxicity [14].
Clinical outcome after discontinuation of treatment
All patients preserved their renal function and showed no
increase of serum baseline creatinine, by 50 or 100% dur-
ing the follow-up period. All patients remained in com-
plete remission of nephrotic syndrome three years after
discontinuation of treatment that was given either for the
first episode of nephrotic syndrome or for treatment of
relapses.
Side effects
Corticosteroidal side effects were observed only in
patients treated with high prednisolone dose. Cushingoid









1st month 10 . 3
2nd month 0.6 0.15
3rd month 0.3 0.10
4th month 0.15 0.07
5th month 0.07 0.07
6th month 0.07 0.07
on alternate day on alternate day
Mean accumulative prednisolone dosage (mg/kgBW) 92.7 ± 22 58.5 ± 21
Mean CsA dosage for target trough levels 100 ng/ml (mg/kgBW/day) - 2.07 ± 0.5BMC Research Notes 2009, 2:144 http://www.biomedcentral.com/1756-0500/2/144
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Individual courses of the urinary protein loss in patients treated by high steroid dose Figure 1
Individual courses of the urinary protein loss in patients treated by high steroid dose.
Individual courses of serum albumin in patients treated by high steroid dose Figure 2
Individual courses of serum albumin in patients treated by high steroid dose.BMC Research Notes 2009, 2:144 http://www.biomedcentral.com/1756-0500/2/144
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Individual courses of the urinary protein loss in patients treated by lower steroid dose and CsA Figure 3
Individual courses of the urinary protein loss in patients treated by lower steroid dose and CsA.
Individual courses of serum albumin in patients treated by lower steroid dose and CsA Figure 4
Individual courses of serum albumin in patients treated by lower steroid dose and CsA.BMC Research Notes 2009, 2:144 http://www.biomedcentral.com/1756-0500/2/144
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was observed in all of them, striae in 4, diabetes mellitus
in 2 and gastrointestinal intolerance in one. Patients
treated with lower prednisolone dose showed no side
effects related to corticosteroids.
Apart from hypertrichosis in 2 patients no other side-
effects related to CsA were observed. In 2 patients with
long-term administration of CsA, no typical lesions of
CsA nephrotoxicity were observed in the repeat biopsies.
Discussion
Steroids represent the cornerstone of treatment in MCD,
but although most patients show complete remission,
31%–76% of them show relapses in various studies. High
daily steroid dose followed by alternate-day administra-
tion, after remission of proteinuria, is used as an initial
treatment in adult MCD. With this therapeutic approach,
remission of the nephrotic syndrome occurs in 46%–62%
at 4 weeks, 67%–87% at 8 weeks and 75%–100% at 16
weeks of treatment [2,8,9,15,16]. A similar response rate,
was observed in this study with high prednisolone dose.
CsA has been used in patients with frequently relapsing,
steroid-dependent and steroid-resistant idiopathic neph-
rotic syndrome [17,18]. Recently, CsA given in combina-
tion with prednisone, to children with steroid-sensitive
nephrotic syndrome, was proved effective in reducing the
number of relapses for the first year of follow-up [13]. The
major problem, with the administration of CsA is its
potential nephrotoxicity [14] and the frequent relapses
after its discontinuation. For this reason, CsA was used at
low doses and stopped after gradual tapering [19]. Com-
bination of low prednisolone dose with CsA has been
used as initial treatment in patients with focal segmental
glomerulosclerosis and obesity, borderline diabetes melli-
tus or osteoporosis, in order to avoid higher steroid doses
[20,21]. In this study, a similar regimen used in adult
MCD patients with relative contraindications to the high
steroid dosage was followed by complete remission in
63% and 100% of patients after 4 and 12 weeks respec-
tively. Although the number of patients was small the
results were comparable to those observed with high pred-
nisolone dose.
A significant problem in patients with minimal changes
disease is the relapse of the nephrotic syndrome within
the first 12 months, after steroid withdrawal (31%–76%).
In our study, relapses occurred in 50% of patients.
Although no significant difference was observed in the
relapse rate between the two groups, a trend towards more
frequent relapses was observed with CsA (40% vs. 63%).
Since prolonged high corticosteroid dose and administra-
tion of cytotoxic drugs are usually followed by serious side
effects, we treated our patients with relapses, with a com-
bination of low prednisolone and CsA. All patients
showed stable remission, probably related to the long
period of maintenance therapy.
The prolonged use of high corticosteroids dose is usually
followed by significant side effects [2,8,9], a finding also
confirmed in our study. However, patients treated with
lower steroid and CsA dose, although treated for longer
period of time, showed no side effects.
In conclusion, treatment of adult MCD with low pred-
nisolone dose and CsA seems to be equally effective with
high prednisolone dose, in the remission rate of nephrotic
syndrome and is less frequently followed by side effects.
However, further research including higher number of
patients treated with low prednisolone dose and CsA, is
required, in order to establish this regimen as initial treat-
ment of adult MCD.
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